Lumos Pharma Inc (LUMO) Return on Investment ROI from the third quarter of 2024 to third quarter of 2023 and for the year 2024, average high and low, overall ranking from Sep 30 2024 to Sep 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Lumos Pharma Inc   (NASDAQ: LUMO)


Lumos Pharma Inc's ROI from its third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Lumos Pharma Inc's ROI in the third quarter of 2024?
Lumos Pharma Inc recorded a cumulative net loss of $-35 million during 12 months ending in the third quarter of 2024, resulting in a negative return on investment (ROI) of -164.99%.

Within the Healthcare sector 788 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2024 from 2855 to 4166.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter
Y / Y Investment Change TTM -60.77 % -53.47 % -46.62 % -40.31 % -36.07 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 11 16 24 34 42
Return On Investment (TTM) -164.99 % -123.99 % -99.85 % -74.08 % -60.85 %
LUMO's Overall Ranking # 4166 # 2855 # 2992 # 3270 # 1971
Seq. Investment Change TTM -26.6 % -22.46 % -19.07 % -14.82 % -12.95 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -35 -36 -37 -34 -33

LUMO Company Profile >> Back to LUMO Roi Comparisons >> See Annual LUMO Return On Investment



Return On Investment LUMO's Ranking
Within: No.
Industry # 368
Sector # 789
Overall # 4166

Return On Investment Statistics
High Average Low
90.08 %
-25.58 %
-164.99 %
(Dec. 30, 2014)   (Sep 30 2024)







Financial Statements
Lumos Pharma Inc's III. Quarter Investments $ 11 Millions LUMO's Balance sheet
Lumos Pharma Inc's III. Quarter Income $ -7 Millions Quarterly LUMO's Income Statement
LUMO's Income by Division See LUMO's Income by Division


LUMO Annual Return On Investment (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019
Total Investments in Millions 34 66 95 123 85
Y / Y Investment Growth -48.76 % -31.1 % -22.35 % 44.27 % -30.41 %
Net Income in Millions -34 -31 -30 -6 -43
Y / Y Net Income Growth - - - - -
Annual Return On Investment -101.27 % -47.36 % -31.97 % -4.62 % -50.6 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LUMO's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LUMO's Competitors
Subscribers only: Roi for Lumos Pharma Inc's Suppliers
Subscribers only: Return On Investment for LUMO's Customers

Other Ratios
LUMO's Roa LUMO's Inventory Turnover Ratio LUMO's Growth Rates LUMO's Dividend Statistics
LUMO's Profitability Ratios LUMO's Asset Turnover Ratio LUMO's Dividend Growth
LUMO's Roe LUMO's Valuation Ratios LUMO's Financial Strength Ratios LUMO's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2024, within Healthcare Sector ROI

Date modified: 2026-08-31T03:26:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.